Fennec Pharmaceuticals Inc. (NASDAQ: FENC)
$5.4800
+0.7600 ( +17.09% ) 259.7K
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.